CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
Abstract Chimeric antigen receptor (CAR)-NK cell therapy has the advantages of a low incidence of side effects and a low cost. However, the clinical outcomes are not satisfactory due to limited antitumor effects and a limited proliferative capacity. Recently, progress in CAR-NK cell therapy has been...
Main Authors: | Ruihao Huang, Qin Wen, Xi Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-04-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13045-023-01435-3 |
Similar Items
-
Biomarkers as targets for CAR-T/NK cell therapy in AML
by: Ruonan Shao, et al.
Published: (2023-06-01) -
Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting
by: Jieyun Xia, et al.
Published: (2023-06-01) -
The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
by: Lara Herrera, et al.
Published: (2021-10-01) -
Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL
by: Guillermo Ureña-Bailén, et al.
Published: (2022-10-01) -
Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies
by: Adrien Krug, et al.
Published: (2021-12-01)